{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:04:50Z","timestamp":1789563890339,"version":"build-2803163510"},"reference-count":68,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The treatment landscape for relapse\/refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) has evolved with recent novel agents. With the availability of novel agents that slow disease progression, managing treatment side effects and monitoring response in patients with these hematologic malignancies may present a challenge for healthcare providers. The imperative to engage patients in the management of their condition demands that specialists are knowledgeable about new treatment options and are skilled and confident in educating patients to manage and monitor for potential side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to establish the current knowledge, skills and confidence levels of oncologists, hematologists and hematologist\u2010oncologists (ONC\/HEM) and identify the challenges they experience when managing and monitoring treatment and engaging patients with CLL or MCL in shared decision\u2010making. The long\u2010term aim is to inform evidence\u2010based continuing medical education to optimize ONC\/HEM competencies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>This cross\u2010sectional study employed a quantitative survey, completed by 285 ONC\/HEM practicing in academic or community settings in Brazil, France, Germany, the United Kingdom, and the United States. Using 5\u2010point Likert\u2010type scales, participants reported their knowledge\/skills\/confidence levels, and their agreement with selected statements. Sub\u2010optimal levels of knowledge\/skills to identify and manage side effects associated with treatments for CLL or MCL were reported. Challenges with patient risk stratification and engaging patients in shared decision\u2010making were reported, with a greater proportion reported by those in community settings. Of note, 31% of participants reported sub\u2010optimal skills identifying patients at higher risk for progression and using stratification to plan and manage treatment, and 58% never\/rarely\/sometimes considered patients' concerns about treatment safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Continuing medical education activities to improve knowledge of new treatments and associated pathways for patients with CLL or MCL, and to develop skills\/confidence to engage in shared decision\u2010making are recommended. Setting\u2010specific issues should be integrated into interventions to ensure relevant educational support for the ONC\/HEM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cnr2.70655","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:03:23Z","timestamp":1786676603000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment, Monitoring, and Management of Patients With Relapsed\/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Evidence From a Multi\u2010Country Needs Assessment"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9278-1718","authenticated-orcid":false,"given":"Patrice","family":"Lazure","sequence":"first","affiliation":[{"name":"AXDEV Group Inc  Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten Utoft","family":"Niemann","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"},{"name":"Department of Hematology Rigshospitalet  Copenhagen Denmark"},{"name":"Santa L\u00facia Hospital  Bras\u00edlia Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1071","authenticated-orcid":false,"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin  Milwaukee Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Ludwig\u2010Maximilians\u2010University Hospital Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Cymbalista","sequence":"additional","affiliation":[{"name":"Avicenne Hospital  Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Peloquin","sequence":"additional","affiliation":[{"name":"AXDEV Group Inc  Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Znamensky","sequence":"additional","affiliation":[{"name":"Lilly Oncology  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Goebel","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Bad Homburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3534-8379","authenticated-orcid":false,"given":"Suzanne","family":"Murray","sequence":"additional","affiliation":[{"name":"AXDEV Group Inc  Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx223"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26367"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26523"},{"key":"e_1_2_12_5_1","unstructured":"Leukemia & Lymphoma Society Mantle Cell Lymphoma Facts. Leuk Lymphoma Soc [Internet]. 2014 https:\/\/www.lls.org\/sites\/default\/files\/file_assets\/mantlecelllymphoma.pdf."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18075"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0054"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-017-0007-7"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.125"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203483"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10215104"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1869966"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473656"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000656"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000464"},{"key":"e_1_2_12_18_1","unstructured":"Lymphoma Coalition Lymphoma Care in Europe 2019 https:\/\/lymphomacoalition.org\/."},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102651"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2227748"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102468"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00645-1"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016685803"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01497-y"},{"key":"e_1_2_12_25_1","volume-title":"Pan\u2010London Haemato\u2010Oncology Clinical Guidelines\u2010Lymphoid Malignancies Part 4: Chronic Lymphocytic Leukaemia (CLL) and B\u2010prolymphocytic Leukaemia (B\u2010PLL)","author":"Samir Agrawal P. J.","year":"2020"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10091682"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.444"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.006"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-585059"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000726"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134934"},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","DOI":"10.1007\/16833_2022_99","volume-title":"A Multidisciplinary Approach to Managing BTK Inhibitor Toxicity in Lymphoma and Chronic Lymphocytic Leukemia","author":"Mu\u00f1oz J. L.","year":"2023"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166804"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00198-2"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.07.017"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/1744987120927206"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.11648\/j.ajtas.20160501.11"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14122.1"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2018.00149"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.4236\/psych.2018.911145"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-06737-1"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12745-1"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.21972"},{"key":"e_1_2_12_44_1","unstructured":"World Health Organization Operational Guidelines for Ethics Committees That Review Biomedical Research 2000 2026 https:\/\/iris.who.int\/handle\/10665\/66429."},{"key":"e_1_2_12_45_1","volume-title":"ICC\/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics","author":"ICC\/ESOMAR","year":"2016"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221116577"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00357-5"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6190-3"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21558"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00662"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.03.005"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12155"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-023-00166-4"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169430"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8262787"},{"issue":"1","key":"e_1_2_12_56_1","article-title":"Exploring the Role of BTK Inhibitors in B\u2010Cell Lymphomas","volume":"1","author":"Tam C. S.","year":"2020","journal-title":"OncologyLive"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001204"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007938"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09189-x"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.137"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-94353-0_37"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020974"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2299737"},{"key":"e_1_2_12_64_1","volume-title":"A Comparative Study of Unmet Information Needs of Patients With Lymphoma and CLL: North America and Europe","author":"Bamigbola O.","year":"2022"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119727"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167610"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2022.151338"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2022.05.009"},{"key":"e_1_2_12_69_1","volume-title":"20\u2009Years After the Start of International Shared Decision\u2010Making Activities: Is it Time to Celebrate? Probably\u2026","author":"Bravo P.","year":"2022"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70655","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.70655","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:16:27Z","timestamp":1789560987000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/cnr2.70655"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70655","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2025-09-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70655"}}